Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Market Cap	35.52B +217.6%
Revenue (ttm)	2.15B +38.2%
Net Income	434.61M +48.6%
EPS	0.99 +33.4%
Shares Out	446.90M
PE Ratio	43.83
Forward PE	42.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,590,500
Open	43.50
Previous Close	41.70
Day's Range	43.30 - 45.80
52-Week Range	24.80 - 80.65
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About HKG:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,922
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2315

Financial Performance

In 2025, HKG:2315's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.36%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error